HSP90AA1 and breast carcinoma: In turn, a next-generation Hsp90 inhibitor Ganetespib (STA-9090, Synta Pharmaceuticals) emerged as a significantly safer alternative25,26 that has so far been evaluated in 38 clinical trials (two of them Phase III), including six on breast cancer.